The Exploratory Clinical Trials on the Primary Safety and Effectiveness of High Myopic Posterior Scleral Fixation System

Not Applicable

• Conditions: High Myopia; Macular Schisis
• Interventions: Device: High Myopic Posterior Scleral Fixation System

• Registration Number: NCT05034016
• Lead Sponsor: GuangZhou WeiShiBo Biotechnology Co., ltd

Brief Summary

The purpose of this study is to assess the primary safety and efficacy of High Myopic Posterior Scleral Fixation System in the treatment of macular schisis caused by high myopia.

Detailed Description

Posterior Scleral Reinforcement（PSR） is the only surgical method that can delay the the development of high myopia. However, The surgical method is restricted by the material source limitation and macular ischemia in the eye after reinforcement. The investigators have designed a new posterior scleral fixation system，Its basic material is medical silicone，The product is designed to solve the problem of material source limitation and macular ischemia in the eye after reinforcement.

Study Timeline

• Study Start: 2020-06-01
• Status Verified: 2021-08
• Study First Submitted: 2021-08-26
• Study First Submitted QC: 2021-09-02
• Last Update Submitted: 2021-09-02
• Study First Posted: 2021-09-05
• Last Update Posted: 2021-09-05
• Primary Completion: 2021-12-31
• Study Completion: 2022-04-24

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Age 18~65, male or female;
2. Refractive ranges from -6.00d to -25.00d;
3. The axial length of the operative eye was 26-32mm;
4. Macular cleavage 200-1000μm;
5. Corrected visual acuity of the operative eye < 0.3;
6. Able to understand the purpose of the test, voluntarily participate and sign the informed consent form.

Exclusion Criteria

1. Known allergy to silica gel and patients with scar constitution;
2. Ocular inflammation;
3. Fundus hemorrhage;
4. Macular hole;
5. Macular cleavage of the contralateral eye greater than 200μm;
6. Corrected visual acuity of contralateral eye < 0.4;
7. Opacity of the refractive medium;
8. Eye tumor;
9. History of hyperthyroidism;
10. Other ophthalmic concomitant diseases that cannot be controlled, such as diabetic retinopathy, hypertensive fundus lesions, optic nerve atrophy, etc.;
11. Severe impairment of liver and kidney function and/or severe systemic diseases (such as cardiovascular, respiratory, digestive, nervous, endocrine, genitourinary, etc., depending on the tolerance of surgery);
12. Women who are pregnant (determined by a blood pregnancy test at the first visit), who are preparing for pregnancy during the test, and who are breastfeeding;
13. a history of drug abuse or alcohol abuse;
14. participate in other drug or medical device clinical trials within 30 days prior to the screening of this clinical trial;
15. Any condition of the subject that the study physician considers to be an impediment to the clinical trial (e.g. subject's susceptibility to mental stress, uncontrollable mood, depression, etc.);
16. Poor compliance of the subject, unable to complete the test process as required.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HM experimental group	High Myopic Posterior Scleral Fixation System	Intraocular implant test product

Primary Outcome Measures

Name	Time	Method
Macular reduction rate	24 weeks	24 weeks after implantation of the High Myopic Posterior Scleral Fixation System

Secondary Outcome Measures

Name	Time	Method
Axial length	Baseline (Before surgery), 24 weeks after surgery	A-scan
Diopter	Baseline (Before surgery), 24 weeks after surgery	Refractometer
Best corrected visual acuity	Baseline (Before surgery), 1 day, 1 week, 4 weeks, 12 weeks, 24 weeks,	ETDRS table

Trial Locations

Locations (1)

The First Affiliated Hospital of Guangzhou University of traditional Chinese Medicine; 🇨🇳 Guangzhou, Guangdong, China